Cotadutide (MEDI0382): Community Protocols & Reports
Aggregated community experiences, protocols, and stacking patterns
Community-Sourced Information
The protocols and reports on this page are gathered from online communities and forums. They represent anecdotal experiences, not clinical evidence. Individual results vary significantly. This information is not medical advice and should not replace consultation with a qualified healthcare provider. Always verify dosing and safety information with peer-reviewed research before making any decisions.
For peer-reviewed dosing protocols, see the clinical dosing guide.
Browse community protocols for all 130 peptides โ
๐TL;DR
- โขCommunity protocols detailed below
- โขEvidence level: Anecdotal Reports
- โขSee community reports below
- โขStacking patterns detailed below
Sources
- Reddit r/Peptides|Dual GLP-1/glucagon agonist discussions(accessed 2026-02-16)
- Reddit r/loseit|Obesity drug pipeline discussions including cotadutide(accessed 2026-02-16)
Community Evidence Overview#
This page documents the community evidence landscape for cotadutide (MEDI0382). This is not clinical evidence and should not be used as medical guidance.
Cotadutide has no community self-experimenter data. It was an investigational pharmaceutical compound developed exclusively within AstraZeneca's clinical trial program and was never available outside of controlled research settings.
Why There Is No Community Data#
Investigational-Only Access#
Cotadutide was only accessible to patients enrolled in AstraZeneca's clinical trials. It was never approved by any regulatory agency and was never manufactured for commercial sale. The proprietary nature of the compound and its development within a major pharmaceutical company meant it was never available through peptide vendors or compounding pharmacies.
Discontinuation in 2023#
AstraZeneca discontinued cotadutide development in April 2023, choosing to advance its next-generation weekly dual GLP-1/glucagon agonist AZD9550 instead. This strategic pivot was influenced by the competitive landscape, where semaglutide and tirzepatide had established dominant market positions.
Clinical Trial Data Summary#
While not community data, cotadutide's phase 2b trials demonstrated meaningful clinical effects:
- Up to 5.0% weight loss at 54 weeks in patients with T2D and obesity
- Significant improvements in liver fat reduction (relevant to NASH)
- GI side effects (nausea, vomiting) consistent with GLP-1 class effects
- Daily subcutaneous injection requirement (a competitive disadvantage versus weekly alternatives)
Current Landscape for Dual Agonists#
The dual GLP-1/glucagon agonist space remains active despite cotadutide's discontinuation. Community interest in this mechanism has grown as the concept of glucagon co-agonism for enhanced metabolic effects gains recognition.
Related Reading#
- Cotadutide Research & Clinical Studies
- Cotadutide Molecular Profile
- Survodutide - Active dual GLP-1/glucagon agonist
- Mazdutide - Another dual agonist in development
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Frequently Asked Questions About Cotadutide (MEDI0382)
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.